Manufacturer record
Rebase Lifescience Pvt. Ltd: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by Rebase Lifescience Pvt. Ltd (Gujarat) were declared Not of Standard Quality between October 2022 and October 2024. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: T23169, Bupropion Hydrochloride Extended Release Tablets U.S.P. 150 mg (Brudel SR-150) (exp Aug 2026). CDTL Mumbai (CDSCO lab) found it not of standard quality: Assay of Bupropion Hydrochloride. Listed in the October 2024 alert.
Records by type
2 records linked to Rebase Lifescience Pvt. Ltd in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Bupropion Hydrochloride Extended Release Tablets U.S.P. 150 mg (Brudel SR-150) | Batch T23169Mfg Sep 2023 · Exp Aug 2026 | Assay of Bupropion HydrochlorideAssay | CDTL MumbaiCDSCO lab | Oct 2024 |
| Ltira ? 250 (Levetiracetam Tablets IP 250 mg) | Batch T22026Mfg Apr 2022 · Exp Mar 2024 | DissolutionDissolution | CDL KolkataCDSCO lab | Oct 2022 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.